Pfizer vs URSAPHARM

10-Q Financial Filing Analysis for Pfizer (2026-08-04)

Pfizer Inc. reported its second-quarter 2026 financial results, with total revenues rising 3% year-over-year to $15.03 billion (up 1% operationally). Operational expansion was led by core franchises including Eliquis (+19% operationally to $2.43 billion), Padcev (+23% operationally to $667 million), and the Vyndaqel family (+8% operationally to $1.76 billion), which offset steep declines in COVID-19 product revenues (Paxlovid down 95% operationally to $21 million; Comirnaty down 34% operationally to $261 million). The company reported a net loss attributable to common shareholders of $(248) million for Q2 2026, compared to net income of $2.91 billion in Q2 2025. This downturn was driven by $4.33 billion in pre-tax intangible asset impairment charges (including $3.8 billion for sigvotatug vedotin following unfavorable Phase 3 trial results and $525 million for Oxbryta), alongside $842 million in legal charges, partially offset by a $1.87 billion net gain on the exit of its ViiV Healthcare investment. Pfizer also expanded its enterprise-wide cost realignment and manufacturing optimization programs, targeting total net cost savings of approximately $6.7 billion and $3.0 billion, respectively, through 2029.

• Q2 2026 total revenues reached $15.03 billion, up 3% YoY (5% operational growth excluding COVID-19 products Comirnaty and Paxlovid).
• Net loss attributable to common shareholders was $(248) million, heavily impacted by $4.325 billion in intangible asset impairments ($3.8 billion for IPR&D sigvotatug vedotin and $525 million for Oxbryta) and $842 million in legal charges.
• Pfizer completed the sale of its 11.7% stake in ViiV Healthcare for $1.875 billion in cash proceeds, realizing a pre-tax net gain of $1.870 billion.

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Investor Presentation Released: Pfizer

AI parsed presentation narrative: Pfizer is demonstrating steady execution and financial outperformance by exceeding revenue and EPS expectations despite the decline in COVID-19 product sales. Management's central thesis focuses on maximizing the value of key acquisitions like Seagen and Metsera to drive post-2028 growth through a high single-digit revenue CAGR and a robust pipeline in oncology and obesity. Key tailwinds mentioned: Acquisition Integration Success, Obesity Pipeline Advancement.

URSAPHARM und der FC Bayern bauen erfolgreiche Partnerschaft weiter aus

Die URSAPHARM Arzneimittel GmbH und der FC Bayern München setzen ihre erfolgreiche Zusammenarbeit fort. Mit HYLO®, dem marktführenden Sortiment im Bereich der Befeuchtung trockener Augen, bleibt URSAPHARM bis 2029 Gold Partner der ersten Herrenmannschaft des deutschen Rekordmeisters. Gleichzeitig wird die Partnerschaft strategisch ausgebaut: Neben einer stärkeren Ausrichtung auf die asiatischen Märkte […]